Latest news with #TRIDENT
Yahoo
5 days ago
- Business
- Yahoo
Avanos Medical Stock Down as Q2 Earnings Miss Estimates, Margins Down
Avanos Medical, Inc. AVNS reported second-quarter 2025 adjusted earnings per share (EPS) from continuing operations of 17 cents, down 50% year over year. The bottom line missed the Zacks Consensus Estimate by 5.6%. GAAP loss per share from continuing operations in the quarter under review was $1.66 against the year-ago period's EPS of 9 cents. Avanos' Revenues Revenues grossed $175 million in the reported quarter, up 1.9% year over year. The metric beat the Zacks Consensus Estimate by 4.7%. Organic sales were up 2% year over year. The top line was boosted bycontinued strong demand and volume across AVNS' Specialty Nutrition Systems ("SNS") portfolio and positive momentum in radiofrequency ablation ("RFA") generator sales, which resulted in more RFA procedures. This was partially offset by lower volume in our surgical pain and recovery portfolio. Shares of the company lost nearly 12.1% at yesterday's close. The company's shares have plunged 37.9% in the year-to-date period compared with the industry's decline of 8.9%. The broader S&P 500 Index has increased 7.3% in the same time frame. Image Source: Zacks Investment Research AVNS' Segmental Analysis Avanos generates revenues from three segments — SNS, Pain Management and Recovery (PM&R) and Corporate and Other. PM&R segment's revenues in the second quarter of 2025 were $61 million, down 2.9% year over year. This figure compares to our second-quarter projection of $71 million. The PM&R segment's volume growth was offset by unfavorable currency effects and the effects of certain revenue streams that Avanos strategically decided not to pursue this year. Net sales of radiofrequency ablation (RFA) products grew 13.7% year over year to $35.8million, reflecting momentum in RFA generator sales. This resulted in more procedures, especially in the ESENTEC and TRIDENT product lines. Net sales in the surgical pain and recovery unit declined 9.4% year over year to $25.2million, in line with AVNS' expectations. SNS segment's revenues in the second quarter of 2025 were $102.7 million, up 5.1% year over year. The segment recorded a 4.4% volume growth driven by continued strong demand across both Avanos' enteral feeding and neonate solutions categories. Enteral feeding unit's revenues were $74.5 million in the second quarter of 2025 (up 2.5% year over year), while Neonate solutions unit's revenues were $28.2 million (up 12.8% year over year). Corporate and Other segment's revenues were $11.3 million, down 23.1% year over year. The segment includes the Hyaluronic Acid (HA) injections and intravenous infusion product lines, which declined primarily due to continued pricing pressures in Avanos' three- and five-shot HA categories. However, in July, AVNS announced the divestiture of its HA product line to Channel-Markers Medical, LLC, a privately held company. This transaction aligns with the company's ongoing transformation, which is focused on advancing its strategic segments in PM&R and SNS. Avanos' Margin Analysis In the quarter under review, Avanos' adjusted gross profit declined 4.7% year over year to $97.4 million. The adjusted gross margin contracted 390 basis points (bps) to 55.7%. We had projected a gross margin of 56.4% for the second quarter. Selling and general expenses increased 3.2% year over year to $83.5million. Research and development expenses decreased 7.9% year over year to $5.8 million. Adjusted operating expenses of $89.3 million increased 2.4% year over year. Adjusted operating profit totaled $12.2 million, reflecting a 44% decrease from the prior-year quarter. The adjusted operating margin in the second quarter contracted 580 bps to 6.9%. AVNS' Financial Update The company exited second-quarter 2025 with cash and cash equivalents worth $90.3 million compared with $97 million at the first-quarter end. Total debt at second-quarter 2025-end was $105.1 million compared with $107.4 million at the first-quarter end. Cumulative net cash provided by operating activities at the end of the second quarter of 2025 totaled $32.5 million compared with $19.8 million in the prior-year period. AVANOS MEDICAL, INC. Price, Consensus and EPS Surprise AVANOS MEDICAL, INC. price-consensus-eps-surprise-chart | AVANOS MEDICAL, INC. Quote Avanos' Guidance AVNS has reiterated its 2025 outlook. The company continues to estimate its net sales for the full year in the range of $665 million to $685 million. The Zacks Consensus Estimate currently stands at $677.1 million. Avanos continues to anticipate 2025 adjusted EPS between 75 and 95 cents. The Zacks Consensus Estimate is currently pegged at 92 cents. Our Take Avanos ended the second quarter of 2025 with mixed results and decent top-line growth. The strength in the SNS segment and RFA product sales of the PM&R segment in the quarter was encouraging. Yet, Avanos' weakness in the PM&R segment and the surgical pain and recovery unit of the same segment was discouraging. Weaknesses in HA injections and intravenous infusion product lines were also disappointing. The contraction of the gross and operating margin does not bode well. Per management, Avanos Medical continues to face a volatile tariff environment in 2025, with management estimating approximately $15 million in incremental manufacturing costs for the year—primarily tied to products sourced from Mexico and China. In the second quarter alone, the company incurred over $8 million in tariffs, partly due to shipments that were still subject to the previous 145% tariff rate on China-origin goods before the U.S. administration reduced it to 30%. These costs are being absorbed into the cost of goods sold, affecting near-term profitability. To mitigate the impact, Avanos is implementing a multi-pronged strategy including internal cost containment, pricing actions, use of temporary tariff exemptions, lobbying efforts, and an accelerated plan to exit China-sourced NeoMed products by the second half of 2026. AVNS' Zacks Rank and Stocks to Consider Avanos currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. MEDP, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today's Zacks #1 Rank stocks here. Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Sustainability Times
02-08-2025
- Science
- Sustainability Times
"China Wants to Catch Ghosts Under the Sea": World's Largest Underwater Telescope Could Unlock the Most Dangerous Secrets of the Universe
IN A NUTSHELL 🌊 TRIDENT is an ambitious project by China to build the world's largest underwater neutrino detector deep in the Pacific Ocean. is an ambitious project by China to build the world's largest underwater neutrino detector deep in the Pacific Ocean. 🔬 The detector aims to capture rare flashes of light caused by elusive neutrinos interacting with water molecules. interacting with water molecules. 💡 With over 24,000 optical sensors, TRIDENT will offer unprecedented sensitivity and a comprehensive all-sky observation capability. 🧩 The project hopes to uncover the origins of cosmic rays and provide insights into ancient cosmic events and new physics. China is embarking on an ambitious project to construct the world's largest neutrino detector deep beneath the ocean. Known as the Tropical Deep-sea Neutrino Telescope (TRIDENT), this advanced scientific instrument will be located 11,500 feet under the surface of the Western Pacific Ocean. Set to be completed by 2030, TRIDENT aims to unravel the mysteries of neutrinos, elusive particles that pass through matter with almost no interaction. By capturing rare flashes of light caused by these ghost particles, scientists hope to trace their origins back to distant cosmic events, potentially expanding our understanding of the universe. The Science Behind Neutrinos Neutrinos are among the universe's most mysterious particles. Every second, about 100 billion of these ghostly particles pass through each square centimeter of the human body without leaving a trace. Neutrinos are produced by nuclear reactions in stars, supernova explosions, cosmic rays, and even human-made particle accelerators. Despite their abundance, they interact very little with other matter, making them incredibly challenging to detect. This elusive nature is why they are often referred to as ghost particles. First discovered in 1956, neutrinos continue to intrigue scientists. They are second only to photons as the most plentiful subatomic particles. However, their lack of an electrical charge and nearly zero mass mean they rarely interact with other particles, which has complicated efforts to study them. By detecting and analyzing neutrinos, researchers hope to gain insights into some of the most energetic and cataclysmic events in the universe. The TRIDENT project represents a significant step forward in this scientific quest. 'They Can Dodge Anything We Throw at Them': China's Secret Algorithm Outsmarts Even America's Most Advanced Hypersonic Defenses TRIDENT's Ambitious Design TRIDENT will feature an impressive arrangement of more than 24,000 optical sensors distributed across 1,211 strings, each extending 2,300 feet upward from the ocean floor. These sensors will be arranged in a Penrose tiling pattern, covering a diameter of 2.5 miles. This extensive setup will allow TRIDENT to scan an enormous volume of ocean water—approximately 1.7 cubic miles—for neutrinos. This makes it far larger and more sensitive than the current largest neutrino detector, IceCube, located in Antarctica, which covers just 0.24 cubic miles. The design of TRIDENT not only increases the likelihood of detecting neutrinos but also enhances the precision with which their origins can be traced. By using Earth as a shield, TRIDENT will detect neutrinos from the opposite side of the planet, allowing for a comprehensive all-sky observation. This groundbreaking project aims to push the limits of neutrino telescope performance and sensitivity, opening new frontiers in astrophysical research. Toyota's $15,000 Electric SUV Is Crushing the Competition in China With Local Tech, High-End Features, and Record Sales The Potential Discoveries The scientific community has high hopes for the discoveries that TRIDENT could facilitate. By capturing and analyzing the rare interactions of neutrinos with water molecules, researchers can trace these particles back to their sources, including ancient stellar explosions and galactic collisions. This ability to look back billions of light-years could provide unprecedented insights into the early universe and the forces that shaped it. Furthermore, by studying neutrinos, scientists hope to uncover the origins of cosmic rays, which remain one of the greatest mysteries in astrophysics. These highly energetic particles strike Earth's atmosphere, producing neutrinos in the process. Understanding cosmic rays may also offer clues about the most powerful particle accelerators in the universe, potentially revealing new physics beyond our current knowledge. 'They Stole Our UFO and Made It Scarier': Pentagon Officials Furious as China Unveils Alien-Looking Surveillance Drone Copy Challenges and Future Prospects Building and operating TRIDENT presents several challenges, including the technical difficulties of installing and maintaining equipment at such great ocean depths. However, the potential rewards are significant. The pilot phase of the project is set to begin in 2026, with the full detector expected to be operational by 2030. As TRIDENT becomes fully operational, it promises to transform our understanding of the universe and the fundamental forces that govern it. As researchers push the boundaries of particle physics and cosmology, TRIDENT stands as a testament to human curiosity and ingenuity. The project not only highlights the collaborative efforts required for such large-scale scientific endeavors but also underscores the importance of exploring the unknown. What new insights might TRIDENT uncover about our universe, and how will these discoveries shape our understanding of the cosmos in the years to come? This article is based on verified sources and supported by editorial technologies. Did you like it? 4.5/5 (28)
Yahoo
28-07-2025
- Business
- Yahoo
Qifu Technology, Inc. (QFIN) to Rebrand as Qfin Holdings
We recently compiled a list of Qifu Technology, Inc. (NASDAQ: QFIN) stands fifth on our list and is currently undergoing a rebranding process. Qifu Technology, Inc. (NASDAQ:QFIN), a leading AI-powered Credit-Tech platform in China, is undergoing a major transformation. The company recently announced it will rebrand as Qfin Holdings, Inc., following shareholder approval in June 2025, marking a strategic shift alongside new leadership appointments and updated governance policies. Recognized as a 'Most Honored Company' in the 2025 Extel Asia Best Managed Teams rankings, the business has earned top accolades for its CEO, CFO, and investor relations team, reflecting its excellence in corporate transparency and execution. Qifu Technology, Inc. (NASDAQ:QFIN) is doubling down on its 'AI + Finance' strategy, with innovations aimed at revolutionizing digital lending and risk assessment. A major highlight is TRIDENT, its proprietary Multimodal Large Language Model (MLLM), designed to enhance fraud detection, streamline customer service, and optimize user experience using multimodal data. A lab technician inspecting a credit card processor chip. The corporation is also expanding through embedded finance channels, with nearly half of the new users in Q1 2025 acquired via APIs. At the same time, it continues to scale its capital-light business model, providing more efficient and lower-risk loan facilitation. With ongoing investment in AI research and partnerships with academic institutions, Qifu Technology, Inc. (NASDAQ:QFIN) is cementing its position as a pioneer in China's evolving fintech landscape. While we acknowledge the potential of QFIN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
